Abstract:e21151 Background: Immunotherapy (IO) is the standard of care in 1L stage IV non-small cell lung cancer (NSCLC) cases that are not eligible for targeted therapies. Today, a level of PD-L1 expression of 50% or above is the only standard predictive biomarker for IO efficacy as monotherapy. However, a majority of patients fail to respond to the treatment and are exposed to potentially severe immune-related adverse events. There is thus an urgent need to discover new predictive signatures of response to IO in such setting. Methods: A retrospective 1-year cohort of 63 patients with advanced NSCLC, PD-L1 expression > 50%, and treated with 1L pembrolizumab monotherapy was analyzed to develop a machine learning-based algorithm predictive of response to immunotherapy. Multimodal baseline data were collected including clinical, biological, pathology, molecular, baseline CT scan data and clinical outcomes status (objective response at first evaluation, PFS, OS). For each patient, thoracic tumors were segmented in 3D by both an experimented pneumologist and a radiologist using the SOPHiA DDM for Radiomics platform. Radiomics features were then extracted following the IBSI standards and combined with the other data modalities. A filter-based variable selection method was applied before testing several machine learning algorithms to obtain an individual prediction of the response at first evaluation. The optimization criterion was the Area Under the ROC Curve (AUC). Due to the small size of the cohort, a nested leave-pair-out cross-validation was used to properly estimate the model performance. Results: A logistic regression algorithm reached an AUC of 0.85, a precision of 83%, a sensitivity of 77% and a specificity of 74% for predicting response at first evaluation. The algorithm was able to correctly predict 21 progressions among 28 observed and 27 disease controls among 35 observed. Features with highest weight were representative of the full scope of data modalities included in the model, highlighting the importance of a truly multimodal analysis. Indeed, withdrawing any specific data modality (e.g., radiomics features), led to a decrease of at least ̃10% of the AUC. Patients were then stratified into two groups, progression versus disease control, based upon their predicted response status at first evaluation. These two groups displayed a statistically significant difference in PFS (p < 0.001), suggesting that baseline multimodal data analysis could help predict long-term outcomes. Conclusions: This proof-of-concept study suggests that machine learning applied to baseline multi-modal data can help predict response to IO at the individual patient level, as well as stratify patients to inform long-term outcomes. This algorithm is being improved and validated through a large real-world multicentric international observational study including more than 4000 patients (DEEP-Lung-IV study, NCT04994795).

Predicting survival and trial outcome in non-small cell lung cancer integrating tumor and blood markers kinetics with machine learning

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

Improving Prediction of Survival and Progression in Metastatic Non-Small Cell Lung Cancer After Immunotherapy Through Machine Learning of Circulating Tumor DNA

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials

Multimodal machine learning model prediction of “individual” response to immunotherapy in 1L stage IV NSCLC.

Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non-small cell lung cancer

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Integrating Knowledge Graphs into Machine Learning Models for Survival Prediction and Biomarker Discovery in Patients with Non–Small-Cell Lung Cancer

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures

Integration of clinical, pathological, radiological, and transcriptomic data improves the prediction of first-line immunotherapy outcome in metastatic non-small cell lung cancer

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer

Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data

Boosting predictive models and augmenting patient data with relevant genomic and pathway information

Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment.

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model

Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade

Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers with Gene-Gene Interactions and Main Effects.

Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy

Machine learning and mechanistic modeling for prediction of metastatic relapse in early-stage breast cancer